DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: PTK787

First Posted Date: 2005-08-24

Last Posted Date: 2015-01-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 5

Registration Number: NCT00134355

Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-07-01

Last Posted Date: 2012-02-07

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 40

Registration Number: NCT00116961

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Phase 2

Terminated

Conditions: Thyroid Cancer

Interventions: Drug: Imatinib

First Posted Date: 2005-06-24

Last Posted Date: 2014-04-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 11

Registration Number: NCT00115739

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus

Phase 2

Completed

Conditions: Esophageal Cancer

First Posted Date: 2004-04-23

Last Posted Date: 2012-12-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 152

Registration Number: NCT00003076

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 2 locations

Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

First Posted Date: 2003-12-16

Last Posted Date: 2012-12-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT00005598

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia

Not Applicable

Completed

Conditions: Cervical Cancer
Precancerous/Nonmalignant Condition

First Posted Date: 2003-12-05

Last Posted Date: 2010-09-22

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 180

Registration Number: NCT00003598

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Phase 2

Completed

Conditions: Nausea and Vomiting
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: ginger extract
Other: placebo

First Posted Date: 2003-07-09

Last Posted Date: 2016-10-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 180

Registration Number: NCT00064272

Locations: 🇺🇸
University of Michigan Cancer Center CCOP Research Base, Ann Arbor, Michigan, United States
🇺🇸
MBCCOP - Our Lady of Mercy Cancer Center, Bronx, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 3 locations

Curcumin for the Prevention of Colon Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-12-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT00027495

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy